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Objective: Post-traumatic knee osteoarthritis (OA) is prevalent after anterior cruciate ligament recon-
struction (ACLR). Biomarkers that identify individuals likely to develop OA, especially symptomatic OA,
can help target preventative and therapeutic strategies. This study examined the magnitude and change
over time in urinary CTX-II (uCTX-II) concentrations shortly after ACL reconstruction, and, secondarily,
the associations with knee pain and function.
Design: Subjects were 28 patients with ACLR and 28 age- and sex-matched controls (CNTRL). Testing was
conducted at four time points spaced 4 weeks apart (4, 8, 12 and 16 weeks post-operative in ACLR).
Measures included demographics, urine samples, Numeric Pain Rating Scale (NPRS) and International
Knee Documentation Committee Subjective Knee Form (IKDC-SKF). uCTX-II concentrations were deter-
mined with competitive enzyme-linked immunosorbent assay (ELISA). uCTX-II concentrations at each
time point in ACLR were compared to the mean concentration over time in CNTRL, with and without
adjustment for body mass index (BMI). Changes over time in each measure and correlations between the
slopes of change were examined.
Results: uCTX-II concentrations were signiﬁcantly higher in ACLR than CNTRL through 16 weeks post-
operative when adjusted for BMI. In ACLR, uCTX-II concentrations signiﬁcantly decreased over time, and
the slope was associated with NPRS (r ¼ 0.406, P ¼ 0.039) and IKDC-SKF (r ¼ 0.402, P ¼ 0.034) slopes.
Conclusion: uCTX-II concentrations shortly after ACLR were elevated compared to CNTRL and declined over
time. Decreasing uCTX-II concentrationswere associatedwith decreasing knee pain and improving function.
uCTX-II may have a role as a prognostic marker following ACLR and warrants further investigation.
 2012 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
An estimated 200,000 anterior cruciate ligament (ACL) injuries
occur in the United States annually, usually during sports partici-
pation,1 and most are treated surgically with an ACL reconstruction
(ACLR).2,3 A prevalent, negative outcome of ACLR is post-traumatic.L. Chmielewski, University of
ons, Department of Physical
4, USA. Tel: 1-352-273-6104;
s Research Society International. Pknee osteoarthritis (OA) development. Within 15 years after ACLR,
up to 80% of the population show radiographic signs of knee OA
including joint space narrowing and osteophyte formation.4e9
Almost half of those with radiographic signs of knee OA also have
symptoms such as pain, swelling and stiffness.4,9 The development
of post-traumatic knee OA has public health implications because
the average age at the time of ACL injury is about 25 years.10 Hence,
knee symptoms and functional limitations will affect a substantial
portion of the life span. On an individual level, the symptoms of
knee OA may also reduce quality of life.4,11 Consequently, there is
a need to implement strategies to post-traumatic knee OA in ACLR
post-surgical care. A critical step toward this goal is achievingublished by Elsevier Ltd. All rights reserved.
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after ACLR.
Knee OA affects all aspects of the joint, but its hallmark feature is
degeneration of articular cartilage.12 Articular cartilage structure is
maintained when chondrocyte metabolism of extracellular matrix
components (synthesis and degradation) is balanced. When degra-
dation exceeds synthesis, articular cartilage structure degenerates.12
Articular cartilage metabolism potentially can be assessed with
biomarkers13 including the crosslinked C-telopeptide fragments of
type II collagen (CTX-II), which is a byproduct of articular cartilage
degradation. CTX-II has been detected in both synovial ﬂuid and
urine. An advantage of urine analysis is urine can be obtained more
easily than synovial ﬂuid,which facilitates a stronger research design
because samples can be collected from a comparable control
(CNTRL) group. However, urine concentrations do not directly
represent the local environment of the joint and instead represent
input from the entire body. In addition, urine concentrations may
reﬂect cartilage activity at the boneecartilage interface.13 Despite
these limitations, urinary CTX-II (uCTX-II) concentrations appear to
have diagnostic and prognostic value for knee OA.13 Studies have
shown that uCTX-II concentrations are elevated in people with
radiographic signs of knee OA,14e17 and generally increase with the
severity of knee OA.14,18e20 In addition, baseline uCTX-II concentra-
tions have been variably associated with knee OA progres-
sion,15,16,21,22 while short-term increases in uCTX-II concentrations
have been associated with both radiographic knee OA progression
and loss of articular cartilage on magnetic resonance images.21,23,24
Concentrations of uCTX-II have been investigated for associations
with the symptoms and functional limitations that can accompany
knee OA. This is important because it would be ideal to identify
people at risk for symptomatic knee OA (i.e., radiographic signs of OA
and knee symptoms, especially pain) because they are most likely to
have functional limitations and seek medical attention. In a pop-
ulation-based study, while the longitudinal trajectory of uCTX-II
over time was positively associated with a knee stiffness rating, no
signiﬁcant association was found with the knee pain rating or score
on the Western Ontario and McMaster Universities Arthritis Index
(WOMAC) physical function sub-scale.23 Similarly, a study of people
with knee OA reported no association between uCTX-II concentra-
tions and the WOMAC index or sub-scale scores.14 Conversely,
subjects with early knee OA (KellgreneLawrence Grade 2) who also
had knee pain demonstrated higher uCTX-II concentrations than
thosewithout knee pain.25 Hence, there is some evidence that uCTX-
II concentrations may be elevated in people with knee symptoms,
making further examination worthwhile.
Previous research in a cross-section of people with ACL injury
found CTX-II concentrations in synovial ﬂuid to be elevated
compared to uninjured CNTRL and to decrease with time from
injury.26 However, to the best of our knowledge, uCTX-II concen-
trations have not been reported following ACLR. It is therefore
unknown if elevated CTX-II concentrations can be detected in urine
shortly after surgery and if concentrations change within a few
months post-operatively. The aim of the current study was to
examine the magnitude and change over time in uCTX-II concen-
trations shortly after ACLR, and, secondarily, the associations with
knee pain and function. We hypothesized that following ACLR,
uCTX-II concentrations would be elevated compared to CNTRL but
decrease over time, and uCTX-II concentrations would be positively
associated with knee pain and negatively associated with knee
function. The early post-operative period was chosen because it is
a time when patients are in supervised rehabilitation and closely
monitored. Therefore, study results can contribute to under-
standing how uCTX-II concentrations respond before structural
damage is evident and provide information that can beneﬁt reha-
bilitation protocols.Methods
Subjects
Patients with an ACLR were recruited from Brooks Center for
Sports Therapy, Jacksonville, FL, USA or the Orthopedic and Sports
Medicine Institute, Gainesville, FL, USA. Eligible subjects were
between 15 and 30 years of age, had surgery less than 1 year after
injury, and participated at least 50 h/year in Level I or II activities
(i.e., sports that include cutting, jumping or pivoting)27 prior to
injury. Potential subjects were excluded from participating if any of
the following were present: bilateral knee injury, prior knee liga-
ment injury and/or surgery, concomitant ligamentous injury
greater then Grade II, articular cartilage defect greater than Grade II
(Outerbridge classiﬁcation), or surgical complications requiring
rehabilitation modiﬁcation. The inclusion and exclusion criteria
were meant to create a population of active subjects with an acute,
unilateral and relatively isolated ACL injury with potential to make
typical progress in rehabilitation.
A cohort of uninjured CNTRL subjectswas recruited from the local
community. Subjects in CNTRL were matched to ACLR by age
(3 years) and sex and were required to participate in high-demand
sports for at least 50 h/year. During the study, subjects in CNTRL
were allowed to participate in up to 10 h of high-impact activity per
week (e.g., Level I or II sports or running and jumping exercises), and
low-impact activity was unrestricted. These parameters were set to
insure that subjects in CNTRL would not signiﬁcantly increase their
high-impact activity over the course of the study.
Subjects gave written consent or assent (minor subjects) to
participate in this study on a form approved by the University of
Florida Institutional Review Board.
Surgical technique and rehabilitation
Surgery for all subjects in ACLR except one was performed by
one of two board-certiﬁed orthopedic surgeons (PAW and MWM).
Surgical procedures were performed using an arthroscopically
assisted technique with anatomic placement of tunnels on the
femur and tibia. After graft harvest and/or preparation, the knee
underwent a diagnostic arthroscopy andmeniscectomy ormeniscal
repair was completed, if applicable. In some cases, a small notch-
plasty was then performed. After drilling the tunnels, the graft was
passed and ﬁxation on the femur was obtained using a cortically
based button (Arthrex or Smith and Nephew). Tibial ﬁxation was
obtained with a bio-absorbable interference screw and when
indicated, backed up with a post or anchor.
Rehabilitation was not controlled in this study. However, the
rehabilitation protocol used at both sites allowed for early weight
bearing without a brace. Rehabilitation interventions were focused
on pain and effusion CNTRL, restoration of knee range of motion,
quadriceps muscle activation and normalization of gait until at least
12 weeks post-surgery. At 12 weeks post-surgery subjects were
allowed to begin advanced activities such as running as long as they
met clinical criteria for knee pain levels, knee range of motion and
quadriceps strength.
Testing protocol
Testing was conducted at four time points spaced 4 weeks apart.
Testing time points corresponded to 4, 8, 12 and 16 weeks after
surgery for ACLR. Testing was spaced at 4-week intervals to allow
ample time for changes in uCTX-II concentrations. The ﬁrst testing
time point was 4 weeks after surgery for ACLR because these
subjects were recruited after surgery, and it was feasible to have
testing coordinated by that time. Demographic information was
T.L. Chmielewski et al. / Osteoarthritis and Cartilage 20 (2012) 1294e13011296collected at the ﬁrst test session. Urine samples and responses on
the Numeric Pain Rating Scale (NPRS) and International Knee
Documentation Committee Subjective Knee Form (IKDC-SKF) were
collected at all time points. Subjects were asked to refrain from
high-impact activity for 24 h before data collection because high-
impact activity has the potential to inﬂuence uCTX-II levels.28,29
Demographic information
Demographic information included age, sex, height (cm), and
weight (kg). Height and weight were measured with a standard
measuring stick and digital bathroom scale, respectively, and used
to calculate body mass index (BMI). Additional information
collected for ACLR included the time from injury to surgery, graft
type, graft source, and any surgical procedures to the meniscus.
Graft type was categorized as “allograft” or “autograft”. The auto-
graft sources were bone-patellar tendon-bone or semi-tendinosus/
gracilis tendons. The allograft sources were tibialis anterior or
Achilles tendons.
uCTX-II
Early morning (within 2 h of waking),30 second void, urine
samples were collected. Samples were immediately put on dry ice
and transported for storage at 20C until analysis. uCTX-II concen-
trations were determined using a commercially available enzyme-
linked immunosorbent assay (ELISA) based on a mouse monoclonal
antibody raised against the EKGPDP sequence of human type II
collagen C-telopeptide (Urine CartiLaps; Nordic Bioscience, Herlev,
Denmark). Urine samplesweredilutedasneeded, ranging from1:2 to
1:60, and were analyzed in duplicate. uCTX-II concentrations were
corrected for urinary creatinine concentration, which was also
determined with ELISA methods (Cayman Chemical Company, Ann
Arbor, MI, USA), using the formula [corrected CTX-II value (ng/
mmol) ¼ 1000  urine CartiLaps (ug/L)/creatinine (mmol/L)]. The
intra-assay coefﬁcient of variation was calculated across multiple
subjects, and inter-assay coefﬁcient of variationwas calculated across
the multiple assays. The average (SD) intra-assay and inter-assay
coefﬁcients of variation were 8.5%  8.9% and 17.6%  14.5%,
respectively.
NPRS
Knee pain intensity in ACLR was measured with an 11-point
NPRS. Subjects verbally rated their worst and least knee pain
intensity in the past 24 h, as well as their current knee pain
intensity, on a scale from 0 (no pain) to 10 (worst pain imaginable)
points. The ratings on these three items were averaged for analysis.
The NPRS has been shown to be a reliable and valid method of
measuring pain.31,32
IKDC-SKF
The 18-item IKDC-SKF was used to assess knee symptoms and
function.33 Point values for each item vary based on the number of
responses possible. Item responses are summed, divided by the
total points possible, and multiplied by 100 to create a total score.
Higher scores indicate less severe knee symptoms and better knee
function. The psychometric properties of the questionnaire were
analyzed in patients with knee problems, including ACL injury, and
a testeretest reliability coefﬁcient (intraclass correlation coefﬁ-
cient) of 0.94,33 a minimal detectable change of 12.8 points,33 and
a standardized response mean of 0.9434 have been obtained.
Normative values have also been determined in a non-patient
population.35Sample size
Power calculations were conducted for the primary objective
with the intent on detecting a group main effect using a two-tailed
test, power of 80%, and alpha of 0.05. Based on uCTX-II concen-
trations reported in older adults with and without severe knee
OA,36 a sample of 12 subjects/group was needed. However, articular
cartilage degradation is likely to be less in patients shortly after
ACLR, which could affect the magnitude of uCTX-II concentrations.
Therefore, to assure that we would detect a smaller difference in
uCTX-II concentrations, we conservatively aimed for a sample size
of at least 24 subjects/group.
Statistical analysis
Statistical analyses were performed with SPSS software, version
20.0 (IBM SPSS Statistics). Descriptive statistics were generated for
all measures. uCTX-II datawere log-transformed prior to analysis to
limit the impact of outliers as has been done in previous reports.17,36
An alpha level of 0.05 was set for signiﬁcance in all statistical tests.
Group differences in log uCTX-II concentrations at each testing
time point were determined with students t-tests for paired
samples. For ACLR, the log uCTX-II concentration at the testing time
point was used; for CNTRL, the mean log uCTX-II concentration
across testing time points was used because the testing time points
had no clinical relevance. Group differences in log uCTX-II concen-
trations were also examinedwith adjustment for differences in BMI
using linear regression models. The mean paired difference
(ACLReCNTRL) in log uCTX-II concentration was the dependent
variable, and the mean paired difference (ACLReCNTRL) in BMI was
the independent variable. By ﬁtting a least squares regression line,
the ﬁtted intercept estimates the mean ACLReCNTRL difference for
the log uCTX-II concentration when the difference in BMI between
ACLR and CNTRL is zero. That is, this analysis adjusts for BMI
differences. For ACLR, the log uCTX-II concentration and BMI at the
testing time point were used; for CNTRL, the mean log uCTX-II
concentration and mean BMI across testing time points were
used. BMI was included in the model because it can inﬂuence the
magnitude of uCTX-II concentrations.37 Age and gender can also
inﬂuence uCTX-II concentrations37 but were not included because
ACLR and CNTRL were matched on these characteristics.
Separate general linear models for repeated measures (time
points) examined changes over time in log uCTX-II concentrations,
NPRS scores, and IKDC-SKF scores. A regression line was ﬁtted
across time points for thesemeasures, and the slopewas computed.
Correlations among these slopes were examined with Pearson’s
Product Moment correlation.
Exploratory analyses in ACLR examined the association of
demographic variables with the mean uCTX-II concentration over
time and the slope of log uCTX-II concentrations over time. Asso-
ciations with age and time from injury to surgery were examined
with Pearson’s Product Moment correlation, and student’s t-tests
for independent samples examined differences based on sex, the
presence of meniscal surgery (yes or no), and graft type.
Results
Demographic data for both groups can be found in Table I. Both
ACLR and CNTRL groups were comprised of 28 subjects, with equal
representation between males and females. The mean [standard
deviation (SD)] difference in age between groups was 0.3 (1.5) years
(Table I) and betweenmatched pairs was 1.2 (0.94) years. Themean
time from injury to surgery ranged from 17 to 278 days in ACLR.
Weight and BMI values were noted to be higher in ACLR and so
these were examined further. The mean weight across testing time
Table I
Demographic information for subjects with ACLR and age- and sex-matched CNTRL
ACLR (n ¼ 28) CNTRL (n ¼ 28)
Female 14 (50%) 14 (50%)
Age (years) 19.6 (4.5) 19.9 (4.3)
Height (cm) 172.5 (9.6) 172.7 (9.2)
Mean weight across
time points (kg)
79.5 (18.1)* 66.7 (12.4)
BMI (kg/m2)
Four weeks post-op
or time point 1
26.2 (5.2)* 22.2 (3.0)
Eight weeks post-op
or time point 2
26.6 (5.2)** 22.2 (2.9)
Twelve weeks post-op
or time point 3
26.7 (5.0)** 22.4 (3.2)
Sixteen weeks post-op
or time point 4
26.9 (5.1)** 22.2 (3.0)















One medial and lateral
menisectomy
One medial meniscal repair
Values are numbers (%) or mean (SD).
*ACLR is greater than CNTRL (P ¼ 0.001).
**ACLR is greater than CNTRL (P < 0.001).
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compared to CNTRL (Table I). Also, BMI values increased over time
in ACLR (Table II).
In ACLR, the mean (SD) uCTX-II concentrations were 3521.2
(4217.5), 3332.8 (3795.1), 3190.5 (3317.9), and 2850.7 (3185.5)
ng/mmol at 4, 8, 12 and 16 weeks post-operative, respectively. In
CNTRL, the mean (SD) uCTX-II concentration across testing time
points was 2827.8 (5033.7) ng/mmol. Log uCTX-II concentrations for
both groups are shown in Fig. 1. Log uCTX-II concentrations were
signiﬁcantly higher in ACLR at 4, 8, and 12 weeks post-operative
compared to the mean log uCTX-II concentration across time points
in CNTRL (P ¼ 0.003, 0.006, 0.021, and 0.081; respectively). The
magnitudeof differencewas0.22 [95%conﬁdence interval 0.08, 0.36],
0.18 [0.06, 0.31], 0.16 [0.03, 0.29], and 0.19 [0.02, 0.25], at 4, 8,12 and
16 weeks post-operative; respectively. Log uCTX-II concentrations
signiﬁcantly declined from 4 to 16 weeks post-surgery in ACLRwhile
no signiﬁcant change over time was found in CNTRL (P ¼ 0.045 and
0.682, respectively; Fig. 1). After adjusting for BMI, log uCTX-II
concentrations were signiﬁcantly higher in ACLR at all time points
compared to the mean log uCTX-II concentration across time points
in CNTRL (P¼ 0.001, 0.029, 0.002, and 0.005; respectively). The BMI-
adjusted magnitude of difference was 2.3 [1.7, 3.1], 2.0 [1.4, 2.7], 2.0
[1.5, 2.8], and 1.8 [1.3, 2.6] fold higher inACLR at 4, 8,12, and 16 weeks
post-operative, respectively.Table II
Scores on the IKDC-SKF in subjects with ACLR and matched CNTRL
Four weeks post-op/time point 1 Eight weeks post-op/time point 2
ACLR* 45.6 (9.5) 57.6 (10.5)
CNTRL 98.7 (3.8) 99.4 (1.7)
The questionnaire was completed at 4-week intervals (4e16 weeks post-operative in AC
whereas scores for CNTRL were near the maximum of 100 at all time points.
Values are mean (SD) points.
*IKDC-SKF scores increased over time (P < 0.001).NPRS scoreswere not acquired for two subjects in ACLR, thus only
26 subjects were analyzed for this measure. Mean NPRS scores
signiﬁcantly decreased over time (P < 0.001) and point values were
2.3 (1.3),1.2 (0.9), 0.8 (0.6), and 1.0 (0.9) at 4, 8,12 and 16 weeks post-
operative; respectively. IKDC-SKF scores signiﬁcantly improved over
time in ACLR (P < 0.001), whereas the scores in CNTRL were close to
themaximumvalue (100points) at each timepoint (Table II). In ACLR,
the mean slope for uCTX-II concentrations was 0.03 (0.06);
however, eight subjects had a positive slope. The slope for log uCTX-II
concentrations in ACLR was positively correlated with the slope for
NPRS scores (r ¼ 0.406, P ¼ 0.039; Fig. 2) and negatively correlated
with the slope for IKDC-SKF scores (r ¼ 0.402, P ¼ 0.034; Fig. 3).
The exploratory analyses in ACLR revealed that the mean log
uCTX-II concentration across time was signiﬁcantly correlated with
age (r ¼ 0.769, P < 0.001), but not time from injury to surgery
(r ¼ 0.284, P ¼ 0.143). The slope of log uCTX-II concentrations was
not signiﬁcantly associated with age (r ¼ 0.302, P ¼ 0.118) or time
from injury to surgery (r ¼ 0.114, P ¼ 0.564). There were no differ-
ences in the log uCTX-II concentration variables between sub-groups
basedon sex, thepresenceofmeniscal surgeryor graft type (Table III).
Discussion
This short-term, longitudinal study provides knowledge about
uCTX-II concentrations in subjects with ACLR, a population at high
risk for developing post-traumatic knee OA. uCTX-II concentrations
in ACLR were highest at the ﬁrst testing time point, 4 weeks post-
operative, and gradually declined until the last testing time point,
16 weeks post-operative. After adjustment for differences in BMI,
log uCTX-II concentrations were found to be elevated in ACLR from
4 to 16 weeks post-operative compared to the mean concentration
across 12 weeks in CNTRL. In ACLR, a greater decline in log uCTX-II
concentrations was correlated with a greater decline in knee pain
intensity and a greater improvement in IKDC-SKF scores. We
interpret these results to indicate that uCTX-II concentrations are
elevated shortly after ACLR, improve with time after surgery, and
may be associated with changes in knee symptoms and function.
Our results indicate that elevated CTX-II concentrations may be
detected in urine in the early period following ACLR. These results
agree with previous ﬁndings of elevated CTX-II concentrations in
synovial ﬂuid after ACLR 26 and an increased percentage of dena-
tured type II collagen at the femoral condyle after ACL injury.38
Thus, uCTX-II concentrations may reﬂect local changes in knee
articular cartilage metabolism. However, the implications of
elevated uCTX-II concentrations on articular cartilage structure
cannot be directly inferred from this study. Future research with
both uCTX-II and articular cartilage structure measures is necessary
to determine whether elevated uCTX-II concentrations are just
a consequence of ACL injury and surgery or predict the develop-
ment and progression of post-traumatic knee OA after ACLR.
CNTRL subjects in this study were physically active in sports,
and their activity level may have inﬂuenced study results. Group
differences would possibly have been magniﬁed with a more
sedentary CNTRL group since higher uCTX-II concentrations have
been reported in athletes compared to non-athletes.28 Nonetheless,Twelve weeks post-op/time point 3 Sixteen weeks post-op/time point 4
66.5 (10.1) 73.7 (11.8)
99.6 (1.0) 99.2 (1.6)
LR). Scores are reported as mean (SD). IKDC-SKF scores increased over time in ACLR,
Fig. 1. Box and whisker plot of log uCTX-II concentrations in subjects with ACLR from 4 to 16 weeks post-surgery (A) and in age- and sex-matched CNTRL subjects at 4 weeks
intervals (B). The mean log uCTX-II concentrations decreased from 4 to 16 weeks post-surgery in ACLR (P ¼ 0.045).
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CNTRL, while in ACLR they demonstrated the capacity to decrease
shortly after surgery. Another study of articular cartilage
biomarkers similarly found a decrease over time after ACL injury.39
However, uCTX-II concentrations increased in eight subjects from
the current study. It cannot be determined why this occurred, but
the temporal pattern is worthy of further investigation because
increasing uCTX-II concentrations have been associated with
articular cartilage degradation in people with knee OA.21,23,24
Subjects in ACLR likely increased their activity level over the
study period and began running and jumping activities. Participa-
tion in sports, especially those that load the lower extremity, can
raise uCTX-II concentrations.28 It is also possible that increasing
lower extremity loading after a period of relative unloading is
detrimental to articular cartilage.40 Therefore, monitoring the effect
of increased activity in the advanced phase of rehabilitation should
be considered in future research.
Ishijima and colleagues25 reported higher uCTX-II concentra-
tions in people with early knee OA who had knee pain. They
speculated the mechanism for pain production might be (1) syno-
vitis resulting from joint debris as articular cartilage degrades; or
(2) pain in peri-articular tissues resulting from altered joint
mechanics as joint structure changes.25 We similarly found
increasing knee pain with increasing uCTX-II concentrations in
ACLR, but themechanism for the association after ACLR is unclear. It
may be due to synovitis that is still present after injury and/or
surgery, or it may be that individuals with higher uCTX-II concen-
trations had worse injury, but this could not be conﬁrmed. TheFig. 2. Slopes for log uCTX-II concentrations and NPRS scores across 4, 8, 12 and
16 weeks post-surgery are positively correlated in subjects with ACLR (r ¼ 0.406,
P ¼ 0.039).association between uCTX-II concentrations and IKDC-SKF scores is
difﬁcult to interpret because the questionnaire contains items
related to knee symptoms and function. The association may reﬂect
higher knee pain and the effect of pain on function. Further
research is needed to explore the mechanisms that link uCTX-II
concentrations to these clinical outcomes.
Within the ACLR group, therewas a negative association between
age and the mean uCTX-II concentration, which agrees with a study
of subjects aged 20e87 years.37 The average age of subjects in our
study was less than 20 years old, and 15 years was the youngest age.
Because uCTX-II concentrations reﬂect input from the entire body,
activity at the growth plate likely contributed to elevated concen-
trations in younger subjects. To the authors’ knowledge, this is one of
the youngest populations studied using uCTX-II. Therefore, ranges of
uCTX-II for normal and diseased states in our study are not compa-
rable to previous knee OA research because most subjects with knee
OA are middle-aged or older. uCTX-II concentrations have ranged
from 190 to 345 ng/mmol in middle-aged to older adult subjects
without knee OA and 344e431 ng/mmol in those with advanced
knee OA,14,23,36 whereas the mean uCTX-II concentrations in our
study were 2,827 ng/mmol in CNTRL and 3,223 ng/mmol in ACLR.
With the study of post-traumatic knee OA in a younger population
increasing, our study demonstrates the importance of age-matching
for CNTRL subjects.While no associations between uCTX-II and other
demographic variables were found, this should be examined in
future research with larger samples.
The main strengths of this study include the inclusion of age- and
sex-matched CNTRL, longitudinal data collection across the early
post-operative period, and a relatively homogeneous population ofFig. 3. Slopes for log uCTX-II concentrations and IKDC-SKF scores across 4, 8, 12 and
16 weeks post-surgery are negatively correlated in subjects with ACLR (r ¼ 0.402,
P ¼ 0.034).
Table III
The mean log uCTX-II concentration and slope of log uCTX-II concentrations between 4 and 16 weeks after ACLR
Sex Meniscal surgery Graft type
Males (n ¼ 14) Females (n ¼ 14) P-value No (n ¼ 18) Yes (n ¼ 10) P-value Allograft (n ¼ 11) Autograft (n ¼ 17) P-value
Mean log uCTX-II concentration 3.32 (0.56) 3.22 (0.36) 0.559 3.24 (0.48) 3.33 (0.46) 0.625 3.26 (0.47) 3.29 (0.49) 0.845
Slope of log uCTX-II concentration 0.02 (0.06) 0.04 (0.06) 0.560 0.04 (0.05) 0.01 (0.07) 0.202 0.04 (0.06) 0.02 (0.06) 0.378
No signiﬁcant differences were found between sub-groups based on sex, the presence of meniscal surgery or graft type. Values are reported as mean (SD).
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considered. The coefﬁcients of variation for uCTX-II analysis are
higher than ideal because some samples were on the low end of the
standard curve, amplifying any differences between calculated
concentrations. Physical maturity was not assessed, thus the effect of
growth plate status on uCTX-II concentrations and potential differ-
ences in growth plate status between matched pairs are unknown.
This study did not include a measure of articular cartilage structure,
so it is unknown if elevated uCTX-II concentrations in this early post-
surgical timeframe are predictive of post-traumatic knee OA devel-
opment. The baseline time point for ACLR was 4 weeks post-surgery
and the time from injury to surgery varied,whichmeans that uCTX-II
concentrations were not measured acutely relative to injury in some
subjects, and the differential effects of injury and surgery on uCTX-II
concentrations cannot be distinguished. In addition, the study period
only extended to 16 weeks post-surgery, which is well before
radiographic signs of OA develop and before subjects resume pre-
injury sport activities. We were unable to CNTRL rehabilitation,
and although a common rehabilitation protocol was followed, it
cannot be determined if subjects began advanced rehabilitation
interventions (e.g., running and jumping) during the study period.
In conclusion, this study provides evidence that between 4 and
16 weeks after ACLR uCTX-II concentrations are elevated compared
to CNTRL and decline over time. The rate of decline in uCTX-II
concentrations was shown to be associated with the rate of
decline in knee pain and rate of improvement in knee symptoms
and function. These ﬁndings provide initial support for further
research of uCTX-II concentrations after ACLR, particularly related
to the effect on articular cartilage structure and the response to
rehabilitation interventions.
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